Each year the company publishes the amount of the remuneration due to the executive directors but does not publish any information on the remuneration policy.
In addition, the company does not submit any resolution that allows shareholders to approve. Therefore, we will recommend opposition of resolution 7 on the discharge for directors, even if this is a mandatory resolution in Luxembourg.
The company proposes two resolution on the renewal of directors. We will support Patrizia Luchetta and Fereshteh Pouchantchi as Directors - both of them are free from conflicts of interest (resolutions 9 and 10).
Eurofins Scientific is an international life sciences company operating in food & pharmaceutical products testings. Co. provides analytical testing services to clients from various industries including pharmaceutical, food, and environmental sectors. Co. offers analytical methods for evaluating the authenticity, origin, safety, identity, composition, and purity of biological substances & products. Co. verifies authenticity of products analyzed to detect dangerous components (pathogens, prions, pesticides, asbestos, mycotoxins, dioxins, toxic substances, etc.). Co. operates in Benelux, France, Germany, North America, Scandinavia, British Isles (U.K. & Republic of Ireland), & other countries.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
>Some key elements: - the slowdown in growth in Q4 (+2.2%) can be explained by the weakness of clinical diagnostic activities in France (one-shot price decrease based on end-of-year price-volume agreements and temporary adjustment and cardiac diagnosis in the US (Boston Heart Diag.)).Excluding these effects, organic growth was of +6%; as a result, the CEO indicated that the guidance of +5% is realistic.In fact, for the first time, the CEO said that routine t...
In general, Lundbergforetagen is in compliance with the Swedish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 12, approval is sought for the re-election of the board of directors. Although there is just sufficient independent representation on the board, ECGS notes that the number of executives (3) sitting on the board is NOT in accordance with provision 4.3 of the Swedish Corporate Governance Code. Aforementioned provision stipulates that no more than one (1) member of the board may be a member of the executive management. Based on the abov...
Merger with Hewlett Packard Enterprise, Profit Warning and Sale of SUSE Business On September 2016, the Company entered into a definitive agreement with Hewlett Packard Enterprise (HPE) on the terms of a transaction which provided for the combination of HPEns software business segment with the Company by way of a merger. The transaction was valued at $8.8bn. On March 2018, the Company issued a profit warning arguing that its revenues declined more than expected due to problems stemming from its acquisition of Hewlett Packard. On 22 March 2018, Hsu resigned from his position of CEO min order to...
Cette année encore, Proxinvest déplore le manque d’informations et de transparence concernant les administrateurs de la société ainsi que la rémunération des mandataires sociaux : aucune information ni biographie n’est disponible sur les membres du conseil. En outre, Proxinvest s’opposera cette année à la politique de rémunération des dirigeants mandataires sociaux en raison du manque de transparence (résolution 5) et sur les montants attribués au cours de l'exercice au Président-Directeur général qui semblent trop élevés au regard de la taille de la société (résolution 6).
Afin de pouvoir remplir au mieux la mission de surveillance et de protection de l’ensemble des actionnaires qui lui incombe, il nous semblerait préférable que le conseil ne soit pas composé de seulement cinq membres dont deux personnes de la famille du principal actionnaire. La société fait preuve de légèreté dans la transparence des informations communiquées aux actionnaires en matière de rémunération. Par conséquent, la plupart des résolutions référentes aux rémunérations des dirigeants connaitront un recommandations négatives au regard de ce manque de transparence. Dans la même optique, ...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.